ERBB2 and breast neoplasm: Upon the analysis of patients with breast tumors classified by HR status (Figure 1B) and HER2 status (Figure 1C), we found that the HR-negative patients had significantly higher levels of PIEZO1 expression than the HR-positive patients (p < 0.0001) (Figure 1B).